Emapalumab in Treatment-Experienced Primary HLH: Safety, Efficacy, and Transplant Outcomes from the Open-Label, Single-Arm Post-Authorization Study Sobi.EMAPALUMAB-104 in Chinese Patients

• EHA •
• 11 June, 2026 •
• •

Emapalumab in Treatment-Experienced Primary HLH: Safety, Efficacy, and Transplant Outcomes from the Open-Label, Single-Arm Post-Authorization Study Sobi.EMAPALUMAB-104 in Chinese Patients

Rui Zhang, Xiaowen Zhai, Andrew Danquah, Ben Peace, Per Hedlund, Andrew Ramsey, Rafael Krmar, Brian Jamieson

• EULAR •
• 5 June, 2026 •
• •

Updated population pharmacokinetic (popPK) model for emapalumab using data from four prospective clinical trials in patients with hemophagocytic lymphohistiocytosis/macrophage activation syndrome (MAS)

Patrick Brossard, Axel Facius, Brian Jamieson

Available materials

• EBMT •
• 23 March, 2026 •
• •

Emapalumab is associated with Rapid and Sustained Benefits in pHLH Subgroups, Including CNS Involvement and Previously Untreated Patients: Analysis of trials NI-0501-04, NI-050105 and NI-050109

Franco Locatelli, Michael B. Jordan, Didier Halimi, Elena Burillo, Brian D. Jamieson, Emmanuel Monnet, Andrew Danquah

Available materials

• EBMT •
• 23 March, 2026 •
• •

Emapalumab induces rapid, durable responses and reliable bridging to curative HSCT in patients with primary HLH: Pooled analysis of prospective trials NI-0501-04, NI-0501-05 and NI-0501-09

Michael B. Jordan, Franco Locatelli, Didier Halimi, Elena Burillo, Brian D. Jamieson, Andrew Danquah, Emmanuel Monnet

Available materials